Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Declines By 67.0%

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a large drop in short interest in the month of February. As of February 13th, there was short interest totaling 20,230 shares, a drop of 67.0% from the January 29th total of 61,344 shares. Based on an average trading volume of 466,445 shares, the days-to-cover ratio is presently 0.0 days. Currently, 3.0% of the company’s stock are sold short. Currently, 3.0% of the company’s stock are sold short. Based on an average trading volume of 466,445 shares, the days-to-cover ratio is presently 0.0 days.

Biodexa Pharmaceuticals Trading Up 0.9%

Shares of Biodexa Pharmaceuticals stock opened at $1.13 on Thursday. The stock has a 50-day simple moving average of $2.02 and a 200-day simple moving average of $4.72. Biodexa Pharmaceuticals has a 52-week low of $1.04 and a 52-week high of $44.40.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on BDRX shares. Wall Street Zen raised shares of Biodexa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Sabby Management LLC purchased a new stake in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals makes up about 0.6% of Sabby Management LLC’s investment portfolio, making the stock its 10th biggest position. Sabby Management LLC owned about 28.04% of Biodexa Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 17.51% of the company’s stock.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.